Waldencast Acquisition Corp. (NASDAQ:WALD) announced this morning that it has added $225 million in debt to its combination with beauty brands OBAGI and Milk.
This new money comes in the form of a four-year secured first-lien made up of a $175 million term loan and a $50 million revolving loan facility with $7.5 million available to be drawn as letters of credit. JP Morgan Chase (NYSE:JPM), Santander (NYSE:SAN) and Wells Fargo (NYSE:WFC) served as joint bookrunners and lead arrangers for the facility with JPM serving as administrative agent and Credit Suisse (NYSE:CS) as documentation agent.
The combined company would now receive $1.02 billion in total proceeds as this debt joins $333 million in forward purchase agreements (FPAs), a $113 million PIPE and Waldencast’s $345 million trust before redemptions. The PIPE and FPAs already covered the $440 million collective minimum cash conditions for the two companies, but the debt further secures all of the uses that the targets had in mind.
At announcement, the parties envisaged paying out $520 million in cash consideration to selling shareholders of the two companies and this new facility is aimed at paying down and replacing all of the companies’ existing credit facilities as well. Even in a 100% redemptions scenario, the combined company is now expected to have about $94 million in new capital to work with after expenses and consideration to sellers.
Waldencast initially announced the $1.2 billion combination with OBAGI and Milk Makeup on November 15. OBAGI provides medical-grade skincare products and Milk Makeup provides clean 100% vegan cosmetics via retail stores and its native ecommerce site.
The parties have not yet set a date for a completion vote on the deal, but on June 13, Waldencast announced an agreement with Obagi and Cedarwalk pertaining to the value of and cost associated with inventory on hand. As of five business days before the special shareholder meeting, the cost of inventory will be deducted from the cash portion of the consideration payable under the Obagi merger agreement to Cedarwalk.
Obagi Hong Kong will pay Obagi and certain affiliates a royalty of 2.75% of gross sales on the specific inventory identified in the agreement that is sold during the 90 days following the completion of the transaction.
At the SPAC of Dawn SPAC momentum has not waned amid the market rally as three more SPACs are angling to price their IPOs by this evening, adding to two others and went public earlier this week. This would bring April’s tally to nine SPAC IPOs after just three in March. It has not been...
New Providence Acquisition Corp. III (NASDAQ:NPACU) announced the pricing of its $261 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NPACU”, Thursday, April 24, 2025. The new SPAC aims to combine with a consumer target that has the potential to generate attractive risk-adjusted returns. New Providence III’s...
Cantor Equity Partners Inc. (NASDAQ:CEP) has entered into a definitive agreement to combine with Twenty One Capital at an enterprise value of $3.6 billion, or 1x its future net asset value (NAV). Twenty One Capital aims to secure a sizeable Bitcoin holding and leverage it for financial services products as well as Bitcoin-focused media offerings....
Voyager (NASDAQ:VACH) has signed a definitive agreement to combine with biotech firm VERAXA at an enterprise value of $1.38 billion. Heidelberg, Germany-based VERAXA is developing cancer treatments with its most advanced candidate targeting acute myeloid leukemia (AML). The combined company is expected to trade on the Nasdaq under the symbol “VERX” once the deal is...
At the SPAC of Dawn SPACs announced two more business combinations and priced a IPO in the past 24 hours showing that activity is going to continue apace regardless of the present market volatility. Another major deal is rumored in the wind with Cantor Equity Partners I (NASDAQ:CEPO) reportedly nearing a major merger that would...